Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development

Immunome, Inc. (NASDAQ:IMNM) is one of the best cancer stocks to invest in now. On February 14, Immunome, Inc. (NASDAQ:IMNM) CEO and Chairman Clay Siegall reiterated heightened focus on building an oncology-focused pipeline centered on cell-surface-targeting agents and small molecules.

The ultimate goal is to develop a targeted oncology platform for small molecules that can overcome resistance and enable bystander activity. The remarks come on the company delivering top-line Phase 3 results for Varegacestat in desmoid tumors. The company is in the process of filing a New Drug Application as it sets its sights on a $1 billion market opportunity, targeting the over 3,000 patients treated annually.

Immunome also plans to submit three additional INDs this year targeting solid tumor programs. The push comes as the company’s radioligand therapy, which delivers radiation directly to tumors, receives FDA clearance. It is poised to start a clinical trial soon.

Immunome, Inc. (NASDAQ:IMNM) is a clinical-stage biotechnology company focused on discovering and developing first-in-class targeted therapies for oncology, primarily using antibody-drug conjugate (ADC) technology. They use a proprietary, memory B cell-based discovery engine to identify novel antibodies that treat cancers.

While we acknowledge the potential of IMNM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best Manufacturing Stocks to Invest In Now and 11 AI Stocks That Will Go to the Moon.

Disclosure: None.  Follow Insider Monkey on Google News.